Marsh S - Search Results

1

Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.

Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K, Figg WD, Verweij J, McLeod HL, Sparreboom A. Smith NF, et al. Among authors: marsh s. Clin Pharmacol Ther. 2007 Jan;81(1):76-82. doi: 10.1038/sj.clpt.6100011. Clin Pharmacol Ther. 2007. PMID: 17186002

2

Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.

Sparreboom A, Gelderblom H, Marsh S, Ahluwalia R, Obach R, Principe P, Twelves C, Verweij J, McLeod HL. Sparreboom A, et al. Among authors: marsh s. Clin Pharmacol Ther. 2004 Jul;76(1):38-44. doi: 10.1016/j.clpt.2004.03.003. Clin Pharmacol Ther. 2004. PMID: 15229462

3

Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.

de Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH, Verweij J, Marsh S, Sparreboom A. de Jong FA, et al. Among authors: marsh s. Clin Pharmacol Ther. 2007 Jan;81(1):42-9. doi: 10.1038/sj.clpt.6100019. Clin Pharmacol Ther. 2007. PMID: 17185998

4

Irinotecan pathway genotype analysis to predict pharmacokinetics.

Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL. Mathijssen RH, et al. Among authors: marsh s. Clin Cancer Res. 2003 Aug 15;9(9):3246-53. Clin Cancer Res. 2003. PMID: 12960109

5

Pharmacogenetics of tipifarnib (R115777) transport and metabolism in cancer patients.

Sparreboom A, Marsh S, Mathijssen RH, Verweij J, McLeod HL. Sparreboom A, et al. Among authors: marsh s. Invest New Drugs. 2004 Aug;22(3):285-9. doi: 10.1023/B:DRUG.0000026254.97350.fe. Invest New Drugs. 2004. PMID: 15122075 Clinical Trial.

6

ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.

de Jong FA, Marsh S, Mathijssen RH, King C, Verweij J, Sparreboom A, McLeod HL. de Jong FA, et al. Among authors: marsh s. Clin Cancer Res. 2004 Sep 1;10(17):5889-94. doi: 10.1158/1078-0432.CCR-04-0144. Clin Cancer Res. 2004. PMID: 15355921

7

Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.

Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Viganò L, Locatelli A, Verweij J, Sparreboom A, McLeod HL. Henningsson A, et al. Among authors: marsh s. Clin Cancer Res. 2005 Nov 15;11(22):8097-104. doi: 10.1158/1078-0432.CCR-05-1152. Clin Cancer Res. 2005. PMID: 16299241 Clinical Trial.

8

Interethnic variability of ERCC2 polymorphisms.

King CR, Yu J, Freimuth RR, McLeod HL, Marsh S. King CR, et al. Among authors: marsh s. Pharmacogenomics J. 2005;5(1):54-9. doi: 10.1038/sj.tpj.6500283. Pharmacogenomics J. 2005. PMID: 15534626

9

Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase.

Ahluwalia R, Freimuth R, McLeod HL, Marsh S. Ahluwalia R, et al. Among authors: marsh s. Clin Chem. 2003 Oct;49(10):1661-4. doi: 10.1373/49.10.1661. Clin Chem. 2003. PMID: 14500593 No abstract available.

10

Caution with beta1-adrenergic receptor genotyping.

Lanfear DE, Marsh S, McLeod HL. Lanfear DE, et al. Among authors: marsh s. Clin Pharmacol Ther. 2004 Aug;76(2):185-6; author reply 186. doi: 10.1016/j.clpt.2004.04.007. Clin Pharmacol Ther. 2004. PMID: 15289795 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,509 results

Search Page